IP Library › Assignment 042392/0981
Patent Assignment
Reel/Frame 042392/0981

Assignment of Assignor's Interest

Recorded: 2017-05-16 Pages: 2
Assignor
RESVERLOGIX CORP.
Executed: 2013-03-01
Assignee
RVX THERAPEUTICS INC.
202,279 MIDPARK WAY SE, CALGARY, AB, T2X 1M2, CANADA
Covered Property (1)
Novel Heterocyclic Compounds as Bromodomain Inhibitors
Patent: 9,861,637 →
Application: 15/424,616 →
Publication: US 2017/0143731
Related Assignments (4)
Other recorded transfers of the patent in this record — the chain of ownership.
Assignment of Assignor's Interest May 16, 2017
From: LIU, SHUANG; DUFFY, BRYAN CORDELL; JIANG, MAY XIAOWU; WANG, RUIFANG
To: RESVERLOGIX CORP.
Reel/Frame 042392/0968 →
Assignment of Assignor's Interest May 16, 2017
From: ZENITH CAPITAL CORP.
To: ZENITH EPIGENETICS LTD.
Reel/Frame 042393/0029 →
General Conveyance and Assumption Agreement May 16, 2017
From: RVX THERAPEUTICS INC.
To: ZENITH EPIGENETICS CORP.
Reel/Frame 042470/0059 →
Change of Name May 16, 2017
From: ZENITH EPIGENETICS CORP.
To: ZENITH CAPITAL CORP.
Reel/Frame 042470/0069 →